Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (18): 3298-3301.doi: 10.3969/j.issn.1673-8225.2011.18.017

Previous Articles     Next Articles

Roles of Genistein combined with subtherapeutic FK506 in the rejection of pancreas transplantation

Zhou Jian, Zhu Xin-guo, Chen Yan, Li De-chun   

  1. Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China
  • Received:2011-03-17 Revised:2011-04-03 Online:2011-04-30 Published:2011-04-30
  • Contact: Li De-chun, Chief physician, Professor, Doctoral supervisor, Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China
  • About author:Zhou Jian☆, Studying for doctorate, Attending physician, Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China zj0612@163.com
  • Supported by:

    Health Science and Education Program of Suzhou City, No. 8WKQ0802*

PDF

300

Abstract:

BACKGROUND: It has been demonstrated that CXCR3-inhibitor Genistein can mitigate the acute rejection of pancreas transplantation efficiently, but the effect of Genistein and FK506 has not been illustrated.
OBJECTIVE: To investigate the role of CXCR3-inhibitor Genistein combined with subtherapeutic FK506 in the rejection of pancreas transplantation. 
METHODS: Five groups of rats underwent pancreas transplantation: the groups were untreated group; large-dose FK506 group; small-dose FK506 group; Genistein group; and Genistein+small-dose FK506 group. The grafts of three groups were harvested at day 7 after operation for histopathology. The expressions of CD3+, CD4+, CD8+T cells in peripheral blood were assessed by FCM, and the levels of interferon gamma (IFN-γ) and interleukin 2 (IL-2) in serum were examined by ELISA. 
RESULTS AND CONCLUSION: The damage of graft tissue in Genistein+small-dose FK506 group significantly alleviated and the infiltration of lymphocytes decreased as compared with untreated group, small-dose FK506 group and Genistein group . It proved that the Genistein+small-dose FK506 combination-therapy could prevent the acute rejection. Genistein+small-dose FK506 combination therapy decreased the dosage of FK506 and prevented the damage effect on the recipients’ hepatic and renal functions. The number of CD3+, CD4+, CD8+ T cells in Genistein+small-dose FK506 group were much less; in addition, down-regulation of IFN-γ, IL-2 in serum were observed in Genistein+small-dose FK506 group. It was demonstrated that CXCR3-inhibitor Genistein combined with  subtherapeutic FK506 could mitigate the acute rejection of pancreas transplantation efficiently and not increase hepatic and renal toxicity.

CLC Number: